Resultados de investigación

Derecho Para Tod@s 1x02 En la segunda entrega de este programa especializado en derecho, conducido por la profesora de la UAL María del Mar Gómez junto a las alumnas Nuria Martínez y Olga Belmonte, el tema central son las compras online. Además, en la sección de "Nuestros expertos", las acompañan las responsables de la comisión de derecho animal del Colegio de Abogados de Almería y en "Juristas noveles", conocemos a Ainhora Sánchez.

Derecho Para Tod@s 1x01 Un espacio dedicado al Derecho, con secciones de actualidad, entrevistas a expertos, contacto con noveles juristas, repaso a la cultura y un rincón para hablar de la igualdad de género en materia legislativa. En este programa se analiza el Derecho animal

Primer programa de la segunda temporada del espacio Derecho Para Tod@s UAL, que coordina la profesora de la UAL María del Mar Gómez. En este espacio colaboran de forma habitual Nuria Martínez y Olga Belmonte. El tema central en el podcast ha sido la Innovación. Además, en la sección "Nuestros Expertos", el profesor Víctor Bastante nos habla de la gamificación en la enseñanza del Derecho, una práctica de innovación docente.

Derecho Para Tod@s 1x03 Programa realizado por María del Mar Gómez, Nuria Martínez y Olga Belmonte. Invitada Mª Ángeles Vila. En el programa de hoy se analiza la legislación en torno a la alimentación.

Programa realizado por María del Mar Gómez, Nuria Martínez y Olga Belmonte. Invitado hoy: Miguel Luque.

Derecho para tod@s - UAL es un Boletín jurídico mensual, cuyo objetivo es divulgar temas jurídicos que puedan ser de interés para la comunidad universitaria y contribuir a la formación integral de los estudiantes de la UAL.

We aimed to compare the efficacy and safety of maintaining or withdrawing abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer who had experienced cancer progression to this treatment and were beginning a docetaxel-based therapy. Phase II, randomised, open-label study conducted in patients with metastatic castration-resistant prostate cancer who were asymptomatic or mildly symptomatic. After open-label treatment with AAP, patients who had experienced cancer progression to AAP were randomised to 75 mg/m2 of docetaxel plus AAP or to receive 75 mg/m2 of docetaxel plus 10 mg of prednisone orally daily. The primary outcome was the radiographic progression-free survival rate at 12 months as evaluated by the investigators in all randomised patients. A total of 148 patients were included in open-label treatment with AAP, and of them, 94 patients were randomised to receive either docetaxel plus AAP (intervention group; n = 47) or docetaxel plus prednisone (control group; n = 47). The 12-month radiographic progression-free survival rates did not differ between the intervention group (34.9%; 95% CI 20.7-49.2) and the control group (33.9%; 95% CI 19.5-48.3). There were no significant differences in the time to radiographic progression and the overall survival between the intervention and control groups. Grade 3-5 neutropenia with the combination of docetaxel plus prednisone and AA was more frequent than with docetaxel plus prednisone (59.6% versus 27.7%). Our results indicate that the therapeutic strategy of maintaining AAP added to docetaxel in chemotherapy-naïve patients who have experienced cancer progression to AAP treatment should not be further evaluated and should be avoided in clinical practice., Si

Recent years have seen great advances in the use of clinical ultrasound imaging in both hospital emergency departments and out-of-hospital settings. However, all new techniques require up-to-date definitions of competencies relevant to the clinical realities of different specialties and the geographic settings in which specialists work. To that end, a group of experts in clinical ultrasound reviewed the evidence available in the literature and strictly applied the Delphi method to define the competencies relevant to emergency physicians. The group worked with the starting premise that clinical ultrasound imaging should be a common competency across the specialty., En los últimos años se han producido grandes avances en el uso de la ecografía clínica tanto en los servicios de urgencias hospitalarios como en el ámbito extrahospitalario. Sin embargo, toda nueva técnica requiere de definiciones actualizadas de competencias relevantes para las realidades clínicas de las diferentes especialidades y los entornos geográficos en los que trabajan los especialistas. Para ello, un grupo de expertos en ecografía clínica revisó la evidencia disponible en la literatura y aplicó estrictamente el método Delphi para definir las competencias relevantes para los médicos de urgencias. El grupo trabajó con la premisa de partida de que la ecografía clínica debería ser una competencia común para toda la especialidad., Yes

Familial chylomicronemia syndrome (FCS) is a rare metabolic disorder caused by mutations in lipoprotein lipase (LPL) or genes required for LPL functionality and is characterized by hyperchylomicronemia that results in recurrent episodes of acute pancreatitis. Owing to the rarity of FCS, there are few case series describing the phenotypic variability in FCS patients in detail. To provide baseline characteristics in the largest study population to date of patients with FCS. We analyzed baseline demographic and clinical characteristics of adult FCS patients in the phase 3 APPROACH study of volanesorsen sodium (antisense inhibitor of apolipoprotein C-III). Sixty-six patients were included in the analysis. Mean (SD) age was 46 (13) years; and mean body mass index was 24.9 (5.7) kg/m2. We identified causal mutations in 79% (52) of patients, with LPL mutations accounting for 62% (41) of cases. Median age at diagnosis was 24 years, 54% were females, and 81% were Caucasian. All patients followed a low-fat diet, 43% received fibrates, 27% fish oils, and 21% statins. Median fasting triglyceride levels (P25, P75) were 1985 (1179, 3047 mg/dL). Overall, 76% of patients reported ≥1 lifetime episode of acute pancreatitis; 23 patients reported a total of 53 pancreatitis events in the 5 years before enrollment. Our data emphasize the severe hypertriglyceridemia characteristic of FCS patients despite restrictive low-fat diets and frequent use of existing hypolipemic therapies. Acute pancreatitis and recurrent acute pancreatitis are frequent complications of FCS. Diagnosis at an older age suggests likely underdiagnosis and underappreciation of this rare disorder., Si

Desmoid fibromatosis (DF) are mesenchymal neoplasms, with potential aggressive course and relevant clinical impact. New systemic therapy modalities are needed in this symptomatic/progressive population. In this multicenter, phase II trial (NCT03275818), patients with symptomatic/progressing DF received three cycles of weekly nab-paclitaxel. Brief pain inventory short form (BPI-SF) was collected at baseline and in every visit. MRI was performed every 3 months. Primary composite endpoint was RECIST 1.1 overall response rate (ORR) and/or clinical response (improvement ≥ 2 points in BPI-SF). If 40% of patients achieved clinical/radiological response, further investigation would be warranted. Toxicity, progression-free survival (PFS), pattern of response and its correlation with clinical best response and BPI, variation of physical function, and analgesic consumption were secondary endpoints. The translational research reported was not a pre-specified secondary outcome. Forty eligible patients started therapy, being 35 radiologically and clinically evaluable. The study achieved its primary endpoint, as 7(20%) patients obtained RECIST partial response, whereas 31(89%) experienced pain reduction of ≥2 points in BPI-SF worst pain. Therapy was well tolerated. With a median follow-up of 30(14-44) months, median 12 and 24-months PFS rates were 91%(CI 95%, 82-100) and 84%(CI 95%, 71-97). For clinical progression, 12 and 24-months PFS rates were 85% (CI 95%, 73-97) and 74% (CI 95%, 58-90) respectively. Short course of nab-paclitaxel is active, safe and achieves quick and durable responses in progressing/symptomatic DF patients., Moura is recipient of a Sara Borrell postdoctoral fellowship funded by the National Institute of Health Carlos III (ISCIII) (CD20/00155). The authors would also like to thank SELNET project. SELNET has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 825806., Si